| A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis HJ Abuhusain, A Matin, Q Qiao, H Shen, N Kain, BW Day, BW Stringer, ... Journal of Biological Chemistry 288 (52), 37355-37364, 2013 | 153 | 2013 |
| Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism H Shen, E Hau, S Joshi, PJ Dilda, KL McDonald Molecular cancer therapeutics 14 (8), 1794-1804, 2015 | 127 | 2015 |
| Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas F Mudassar, H Shen, G O’Neill, E Hau Journal of Experimental & Clinical Cancer Research 39 (1), 208, 2020 | 101 | 2020 |
| Dual-targeting of aberrant glucose metabolism in glioblastoma H Shen, S Decollogne, PJ Dilda, E Hau, SA Chung, PP Luk, PJ Hogg, ... Journal of Experimental & Clinical Cancer Research 34, 1-11, 2015 | 76 | 2015 |
| Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas H Shen, M Yu, M Tsoli, C Chang, S Joshi, J Liu, S Ryall, Y Chornenkyy, ... Neuro-oncology 22 (1), 139-151, 2020 | 55 | 2020 |
| Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma M Tsoli, J Liu, L Franshaw, H Shen, C Cheng, MS Jung, S Joshi, A Ehteda, ... Oncotarget 9 (7), 7541, 2018 | 37 | 2018 |
| Targeting glucose metabolism of cancer cells with dichloroacetate to radiosensitize high-grade gliomas KM Cook, H Shen, KJ McKelvey, HE Gee, E Hau International Journal of Molecular Sciences 22 (14), 7265, 2021 | 35 | 2021 |
| International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma M Tsoli, H Shen, C Mayoh, L Franshaw, A Ehteda, D Upton, D Carvalho, ... Journal of neuro-oncology 141, 253-263, 2019 | 35 | 2019 |
| Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas H Shen, K Cook, HE Gee, E Hau Journal of experimental & clinical cancer research 39 (1), 129, 2020 | 30 | 2020 |
| The evolving roles and controversies of radiotherapy in the treatment of glioblastoma E Hau, H Shen, C Clark, PH Graham, ES Koh, K L. McDonald Journal of medical radiation sciences 63 (2), 114-123, 2016 | 25 | 2016 |
| Constitutive CHK1 expression drives a pSTAT3–CIP2A circuit that promotes glioblastoma cell survival and growth A Khanna, JAI Thoms, BW Stringer, SA Chung, KS Ensbey, TR Jue, ... Molecular Cancer Research 18 (5), 709-722, 2020 | 23 | 2020 |
| Short diffusion time diffusion-weighted imaging with oscillating gradient preparation as an early magnetic resonance imaging biomarker for radiation therapy response monitoring … A Bongers, E Hau, H Shen International Journal of Radiation Oncology* Biology* Physics 102 (4), 1014-1023, 2018 | 18 | 2018 |
| 缺血性脑血管病的外科治疗 沈涵， 柳成荫， 石祥恩 国际脑血管病杂志, 214-218, 2010 | 5 | 2010 |
| Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment F Mudassar, H Shen, KM Cook, E Hau Journal of Medical Imaging and Radiation Oncology 66 (4), 560-574, 2022 | 4 | 2022 |
| DD-04 PENAO: A POTENT MITOCHONDRIAL TARGETED INHIBITOR FOR GLIOBLASTOMA S Chung, S Decollogne, P Luk, H Shen, W Ha, B Day, B Stringer, P Hogg, ... Neuro-Oncology 16 (suppl_5), v60-v61, 2014 | 4 | 2014 |
| CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration Y Dong, S Gao, X Zhang, J Kou, J Liu, T Ye, H Shen Anti-Cancer Drugs 33 (2), 149-157, 2022 | 3 | 2022 |
| Preclinical evaluation of Penao: a potent mitochondrial specific, arsenical-based inhibitor for Glioblastoma S Chung, P Decollogne, P Luk, H Shen, W Ha, B Day, B Stringer, P Hogg, ... Neuro-Oncology 15, 40-40, 2013 | 3 | 2013 |
| PENAO, a novel mitochondria-targeted agent, has shown potent antitumor effect on glioblastoma in vitro and in vivo. H Shen, PP Luk, SA Chung, S Decollogne, PJ Dilda, PJ Hogg, ... Cancer Research 73 (8_Supplement), 1701-1701, 2013 | 3 | 2013 |
| The complexities of resistance to bevacizumab H Shen, KL McDonald Scientific Research Publishing, 2012 | 3 | 2012 |
| Targeting glioblastoma metabolism with a novel arsenic-based metabolic inhibitor, Penao SA Chung, KL McDonald, H Shen, BW Day, BW Stringer, T Johns, ... Neuro-Oncology 13, 118-118, 2011 | 3 | 2011 |
Philip HoggUniversity of SydneyDirección de correo verificada de sydney.edu.au
